World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Amgen and Zai Lab eye a gastric niche
Adverse events will be closely watched when full data are reported.
DLL3 goes trispecific
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
Akeso looks early in small-cell lung cancer
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
Merck speeds its KRAS into the colorectal front line
The move follows promising but early data presented at ASCO.
